Nanox Highlighted on TIME's Best Inventions of 2024 List for its AI Solutions
Nanox AI, a subsidiary of NANO-X IMAGING (NNOX), has received a Special Mention in TIME's Best Inventions of 2024 list for its innovative medical imaging analytics solutions. The company's FDA-cleared AI technology analyzes routine CT scans to detect early signs of chronic conditions in cardiac, liver, and bone health. Their solutions include HealthCCSng for coronary artery calcification measurement, HealthOST for spine analysis, and HealthFLD for liver evaluation, all aimed at identifying previously undetected asymptomatic conditions to promote preventive care management.
Nanox AI, una sussidiaria di NANO-X IMAGING (NNOX), ha ricevuto una Menzione Speciale nella lista delle Best Inventions of 2024 di TIME per le sue soluzioni innovative di analisi di imaging medico. La tecnologia AI dell'azienda, approvata dalla FDA, analizza le scansioni CT di routine per rilevare i segni precoci di condizioni croniche nella salute cardiaca, epatica e ossea. Le loro soluzioni includono HealthCCSng per la misurazione della calcificazione delle arterie coronariche, HealthOST per l'analisi della colonna vertebrale, e HealthFLD per la valutazione del fegato, tutte finalizzate a identificare condizioni asintomatiche precedentemente non diagnosticate per promuovere una gestione della cura preventiva.
Nanox AI, una subsidiaria de NANO-X IMAGING (NNOX), ha recibido una Mención Especial en la lista de TIME's Best Inventions of 2024 por sus soluciones innovadoras de análisis de imagen médica. La tecnología de IA de la compañía, aprobada por la FDA, analiza las tomografías computarizadas (CT) rutinarias para detectar signos tempranos de afecciones crónicas en la salud cardíaca, hepática y ósea. Sus soluciones incluyen HealthCCSng para la medición de la calcificación de las arterias coronarias, HealthOST para el análisis de la columna vertebral, y HealthFLD para la evaluación del hígado, todas orientadas a identificar condiciones asintomáticas no detectadas previamente para promover la gestión del cuidado preventivo.
Nanox AI는 NANO-X IMAGING (NNOX)의 자회사로, 혁신적인 의료 영상 분석 솔루션으로 TIME의 2024년 최고의 발명 목록에서 특별 언급을 받았습니다. 이 회사의 FDA 승인 AI 기술은 일상적인 CT 스캔을 분석하여 심장, 간 및 뼈 건강에서 만성 질환의 초기 징후를 감지합니다. 이들의 솔루션에는 관상동맥 칼슘화를 측정하는 HealthCCSng, 척추 분석을 위한 HealthOST, 간 평가를 위한 HealthFLD가 포함되어 있으며, 모두 예방 관리 강화를 위해 이전에 발견되지 않은 무증상 질환을 식별하는 데 중점을 두고 있습니다.
Nanox AI, une filiale de NANO-X IMAGING (NNOX), a reçu une Mention Spéciale dans la liste des Best Inventions of 2024 de TIME pour ses solutions innovantes d'analyse d'images médicales. La technologie IA de l'entreprise, approuvée par la FDA, analyse les scanners CT de routine pour détecter les premiers signes de maladies chroniques liées à la santé cardiaque, hépatique et osseuse. Leurs solutions comprennent HealthCCSng pour la mesure de la calcification des artères coronaires, HealthOST pour l'analyse de la colonne vertébrale et HealthFLD pour l'évaluation du foie, toutes visant à identifier des conditions asymptomatiques jusqu'alors non détectées afin de promouvoir la gestion des soins préventifs.
Nanox AI, eine Tochtergesellschaft von NANO-X IMAGING (NNOX), hat eine besondere Erwähnung in der Liste der Best Inventions of 2024 von TIME für ihre innovativen medizinischen Bildgebungsanalyselösungen erhalten. Die von der FDA zugelassene KI-Technologie des Unternehmens analysiert Routine-CT-Scans, um frühzeitig Anzeichen chronischer Erkrankungen der Herz-, Leber- und Knochengesundheit zu erkennen. Zu ihren Lösungen gehören HealthCCSng zur Messung der Verkalkung der Koronararterien, HealthOST zur Analyse der Wirbelsäule und HealthFLD zur Bewertung der Leber, die alle darauf abzielen, zuvor unentdeckte asymptomatische Zustände zu identifizieren, um das Management präventiver Maßnahmen zu fördern.
- Recognition in TIME's Best Inventions of 2024 list enhances company visibility and credibility
- Multiple FDA 510(k) clearances for AI solutions in cardiac, bone, and liver analysis
- Technology enables early detection of asymptomatic conditions through routine CT scans
- None.
Insights
This recognition from TIME, while prestigious, lacks direct financial or operational impact on Nanox. Their AI solutions for medical imaging analysis, though FDA-cleared and innovative, are already in the market. The special mention highlights three key products: cardiac plaque detection, spine analysis and liver assessment tools - but provides no new information about market penetration, revenue generation, or business growth.
The recognition may provide some marketing value and brand visibility, potentially helping with future sales efforts. However, for a company with a
Nanox AI’s Solutions selected for Special Mention on annual list recognizing the most impactful new products and ideas
PETACH TIKVA, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, NanoxAI Ltd. (Nanox AI), was selected for a Special Mention in the TIME’s Best Inventions of 2024 list.
TIME’s annual Best Inventions list celebrates the most groundbreaking products and ideas that are shaping industries and enhancing lives. As noted by TIME, Nanox AI was highlighted as one of the most impactful new products, using “AI to help identify asymptomatic undetected chronic conditions early by analyzing routine medical CT scans.”
“We are honored to receive this recognition from TIME,” said Erez Meltzer, Nanox's Chief Executive Officer and Acting Chairman. “This validates our AI technology's success in helping clinicians detect early signs of chronic and acute diseases. As a leader in end-to-end medical imaging innovation, we're committed to improving patient outcomes through earlier detection and preventive care.”
Nanox AI’s special mention can be viewed here: Nanox.AI Solutions for Medical Imaging: the 200 Best Inventions of 2024 | TIME
Nanox AI’s FDA-cleared solutions analyze routine CT scans performed for any clinical indication to help identify patients with findings correlated with chronic conditions in cardiac, liver and bone, with the goal of promoting preventive care management. These chronic conditions are often asymptomatic and previously undetected in patients.
Nanox AI's following solutions have each received FDA 510(k) clearance:
- AI Cardiac solution (HealthCCSng) measures calcified plaques in the coronary arteries, which present a risk for coronary artery disease.
- AI Bone solution (HealthOST) provides qualitative and quantitative analysis of the spine from CT images to support clinicians in the evaluation and assessment of musculoskeletal disease of the spine.
- AI Liver solution (HealthFLD) provides quantitative and qualitative analysis of the liver from CT images to support clinicians in the evaluation and assessment of Fatty Liver.
About Nanox AI
Nanox AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox AI’s solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI technology, Nanox AI helps clinicians extract valuable and actionable clinical insights from routine medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit https://www.nanox.vision/ai.
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and novel digital source.
Nanox's vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI for smarter diagnostics and maintaining a clinically-driven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source Digital Tomosynthesis system that is cost-effective and user-friendly; Nanox.AI – an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD – a cloud-based software platform that manages and stores data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance its better health outcomes worldwide. For more information, please visit www.nanox.vision.
Contacts
Media Contact:
Ben Shannon
ICR Westwicke
NanoxPR@icrinc.com
Investor Contact:
Mike Cavanaugh
ICR Westwicke
mike.cavanaugh@westwicke.com
FAQ
What recognition did Nanox (NNOX) receive from TIME magazine in 2024?
What FDA-cleared AI solutions does Nanox (NNOX) currently offer?
How does Nanox (NNOX) AI technology improve patient care?
